| ID Source | ID |
|---|---|
| PubMed CID | 159837 |
| MeSH ID | M0206327 |
| Synonym |
|---|
| bis(cyclohexylammonium)sulfate |
| cyclohexylamine, sulfate (2:1) |
| 17911-61-4 |
| einecs 241-855-1 |
| cyclohexylammonium sulphate (2:1) |
| DTXSID80170770 |
| cyclohexylammonium sulfate (2:1) |
| cyclohexanamine;sulfuric acid |
| cyclohexylamine hemisulfate |
| WZBMSCFCEJIJSE-UHFFFAOYSA-N |
| cyclohexanamine hemisulfate |
| Excerpt | Reference | Relevance |
|---|---|---|
| "During the COVID-19 pandemic, government directives for health and community services focused on building capacity for COVID-19 safe behaviors." | ( Codesign and community outreach to create COVID-19 safe communities: A Karen community case study. Davis, H; Elmer, S; Graves, K; Learmonth, C, 2023) | 0.91 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||